Hepatitis B

Hepatitis B is a potentially life-threatening liver infection caused by the Hepatitis B virus (HBV). It is a major global health hazard that can cause acute illness or transition into a chronic infection, significantly increasing the risk of death from cirrhosis and hepatocellular carcinoma (HCC).

HBV is a small, enveloped, partially double-stranded DNA virus belonging to the Hepadnaviridae family. Transmission occurs through percutaneous or mucosal exposure to infectious blood or body fluids (semen, vaginal secretions). Major routes include vertical transmission (mother-to-child at birth), unsafe injection practices, blood transfusions, and unprotected sexual contact.

HBV is not directly cytopathic to hepatocytes. Liver injury is primarily immune-mediated. Cytotoxic T-lymphocytes (CD8+ T-cells) target HBV-infected hepatocytes displaying viral antigens (HBsAg, HBcAg) complexed with MHC Class I molecules. This immune response triggers hepatocyte apoptosis, lobular inflammation, and subsequent fibrogenesis. Persistent viral replication and inadequate immune clearance lead to chronic necroinflammation and progressive hepatic fibrosis.

Globally, approximately 296 million people live with chronic HBV infection, with over 820,000 deaths annually. Prevalence is highest in the Western Pacific and African regions. Chronicity risk is inversely proportional to the age of acquisition: 90% in infected infants versus <5% in healthy adults.

• Perinatal exposure (infants born to HBsAg-positive mothers)
• Intravenous drug use (sharing needles)
• Unprotected sexual contact with multiple partners
• Occupational exposure (healthcare workers)
• Hemodialysis recipients
• Travel to endemic areas

• Vitals: Usually stable; low-grade fever may be present in acute phases.
• Inspection: Scleral icterus, jaundice, spider angiomas, palmar erythema, muscle wasting, gynecomastia.
• Palpation: Tender hepatomegaly, splenomegaly, fluid wave (ascites).
• Neurological: Asterixis (flapping tremor) in advanced hepatic encephalopathy.

• A. Clinical Assessment: Comprehensive history focusing on risk factors, vaccination status, and symptoms.
• B. Laboratory Testing: Serological markers (HBsAg, anti-HBs, anti-HBc IgM/IgG, HBeAg, anti-HBe) and HBV DNA viral load.
• C. Imaging Studies: Abdominal ultrasound to assess liver morphology, portal vein patency, and screen for HCC.
• D. Functional Tests: Serum liver enzymes (ALT, AST), bilirubin, albumin, and Prothrombin Time (PT/INR).
• E. Biopsy Findings: Liver biopsy shows lobular inflammation, hepatocyte ballooning, ground-glass hepatocytes (HBsAg accumulation), and varying degrees of portal fibrosis.
• F. Genetic Testing: Viral genotyping (A-J) to guide treatment response.
• G. Differential Diagnosis: Differentiating HBV from other viral hepatitides, autoimmune hepatitis, and drug-induced liver injury.

Abdominal Ultrasound: Purpose: Evaluate liver structure and screen for focal lesions (HCC). Typical Findings: Hyperechoic or heterogeneous liver parenchyma, nodularity (cirrhosis), splenomegaly. Clinical Importance: Essential first-line surveillance tool for chronic carriers.
Transient Elastography (FibroScan): Purpose: Non-invasive assessment of liver stiffness (fibrosis stage). Typical Findings: Measured in kilopascals (kPa); high values correlate with advanced fibrosis or cirrhosis. Clinical Importance: Reduces the need for invasive liver biopsies.

• Hepatitis A and C: Differentiated by positive anti-HAV IgM or anti-HCV/HCV RNA tests.
• Drug-Induced Liver Injury (DILI): Associated with specific hepatotoxic drugs (e.g., acetaminophen); serologies negative for viral markers.
• Autoimmune Hepatitis (AIH): Characterized by positive ANA, ASMA, and elevated IgG levels.
• Wilson's Disease: Distinguished by low ceruloplasmin and elevated urinary copper.

• Cirrhosis
• Hepatocellular Carcinoma (HCC)
• Acute Liver Failure (Fulminant Hepatitis)
• Portal Hypertension (ascites, varices)
• Glomerulonephritis (membranous or membranoproliferative)

Acute HBV in adults has an excellent prognosis, with >95% recovering fully. Chronic HBV has a highly variable course; without treatment, 15-25% of chronic carriers die prematurely from cirrhosis or hepatocellular carcinoma.

• Primary: Hepatitis B recombinant vaccine series; needle exchange programs; safe sex practices.
• Secondary: Screening pregnant women; screening high-risk populations; antiviral therapy to reduce vertical transmission.

The following homeopathic remedies have been historically indicated for symptoms associated with Hepatitis B. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

📊 Advanced Liver Function & Fibrosis Analyzer

Comprehensive multi-metric clinical liver analyzer. Simultaneously evaluates AST, ALT, Platelets to compute De Ritis Ratio, APRI Score, and FIB-4 Index for fibrosis staging.